Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial

Guidelines for Improving Entry Into and Retention in Care and Antiretroviral Adherence for Persons With HIV: Evidence-Based Recommendations From an International Association of Physicians in AIDS Care Panel

Melanie Thompson, Michael J. Mugavero, K. Rivet Amico et al. · Annals of Internal Medicine · 2012 · 594 citations · Full text

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Josep M. Llibre, Chien‐Ching Hung, Cynthia Brinson et al. · The Lancet · 2018 · 338 citations

Treatment And Prevention, Human Retrovirus, Antiviral Therapy +8

Lipid Profiles in HIV‐Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles?

Éric Fontas, Frank van Leth, Caroline Sabin et al. · The Journal of Infectious Diseases · 2004 · 334 citations · Full text

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

Eric S. Daar, Edwin DeJesus, Peter Ruane et al. · The Lancet HIV · 2018 · 168 citations

Hiv/aids Counselling, Treatment And Prevention, Antiviral Drug Development +9

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial

Chloe Orkin, Kathleen Squires, Jean‐Michel Molina et al. · Clinical Infectious Diseases · 2018 · 159 citations · Full text